Paragonix’s LIVERguard Used in 1st Pediatric Case

Paragonix has completed the first liver transplant case with a pediatric donor liver preserved using its LIVERgiard donor liver preservation system. The liver was successfully transplanted by Dr. Deepak Vikraman at Duke University Hospital in Durham, N.C.
 
LIVERguard launched in 2022 and has been used in more than 300 liver transplant cases in the U.S. This case is the first in the pediatric setting.
 
“This case exemplifies the importance of employing the latest innovations in transplant preservation within pediatric care,” said Dr. Vikraman, liver transplant surgeon at Duke. “New technologies are pushing the boundaries of what was previously possible. By advancing preservation methods, we can expand donor pools and offer young patients a second chance at life.”
 
LIVERguard offers a controlled environment for hypothermic liver preservation. This is aided by real-time digital monitoring to protect the donor liver throughout the transplant process. The technology advances organ transplantation technology, aiming to replace the methods of using ice and off-the-shelf coolers.
 
“We are thrilled to see our technology utilized in the pediatric setting, extending its impact to more liver transplant patients and improving preservation techniques and outcomes for children,” said Dr. Lisa Anderson, CEO and President of Paragonix Technologies. “Partnering with a leading pediatric liver transplant center like Duke University, whose mission it is to provide extraordinary care aligns perfectly with our vision of improving outcomes. It is truly exciting to work together to transform the healthcare system for the better.”
 
In June, Paragonix launched the FDA-cleared PancreasPak device to protect and monitor donor pancreases during transportation.